Marc J. Braunstein, MD, PhD

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

When treating cancers that are considered generally incurable, such as multiple myeloma, one of the paradigms in oncology is to deliver the most effective therapies upfront to maximize the chances of prolonging remission.

Marc J. Braunstein, MD, PhD, discusses the role of daratumumab in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses management strategies in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.

In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses the utility of maintenance therapy in patients with multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses challenges pertaining to the bone marrow microenvironment in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses the ultra–high-risk patient population in smoldering multiple myeloma.